Clinical consequences of tocilizumab consumption time on COVID-19 patients

Keshtkar Rajabi, Shahin; Ziaee, Amir; Divsalar, Farshad; Hemmati, Elnaz; Abbasi, Mohammad Amin

doi:10.61186/rabms.10.4.310

Volume 10, Issue 4 (11-2024) Journal of Research in Applied and Basic Medical Sciences 2024, 10(4): 310-317 | Back to browse issues page

‎ 10.61186/rabms.10.4.310

Mendeley

Zotero

RefWorks

Keshtkar Rajabi S, Ziaee A, Divsalar F, Hemmati E, Abbasi M A. Clinical consequences of tocilizumab consumption time on COVID-19 patients. Journal of Research in Applied and Basic Medical Sciences 2024; 10 (4) :310-317
URL: http://ijrabms.umsu.ac.ir/article-1-289-en.html

Clinical consequences of tocilizumab consumption time on COVID-19 patients

Shahin Keshtkar Rajabi

, Amir Ziaee

, Farshad Divsalar

, Elnaz Hemmati

, Mohammad Amin Abbasi ^*

Assistant Professor, Firoozabadi hospital clinical research development unit (FHCRDU), Department of internal medicine, school of medicine, Iran University of Medical Sciences (IUMS), Tehran, Iran , Amin.abbasi1314@gmail.com

Abstract: (315 Views)

Background & Aims: Studies have shown that treating COVID-19 with tocilizumab is associated with lower death risks and mechanical ventilation needs. However, the definite effectiveness of this drug based on the timing of its use is still controversial due to various findings. Some studies have shown that the timing of consumption can impact the drug’s effectiveness.
Materials & Methods: This retrospective study was conducted on all COVID-19 patients who were treated with tocilizumab (Actemra) from August 2020 to August 2021 at Firoozabadi Hospital, Tehran. Demographic, laboratory, and clinical information of the patients were extracted from patient records. SPSS v22 software was used for data analysis.
Results: In this study, we analyzed data from 344 patients with an average age of 57.31 ± 14.75 years (range: 19-95). The cohort included 186 men (54.06%) and 158 women (45.94%). Most patients (70.9%) received the drug between the second and fifth day of hospitalization. Overall, 104 patients (30.2%) died during their stay. Among those who received the medication twice, 38 out of 118 died, while 66 out of 224 died after a single dose. The highest mortality rate was observed in patients who received the drug after five days (39 deaths), and the age group of 60-95 had the highest percentage of deaths, totaling 58 (55.76%). Female patients also exhibited a higher mortality rate at 60.57% (63 deaths).
Conclusion: Therefore, it seems that the best time to prescribe tocilizumab to COVID-19 patients is between the 2^nd and 5^th day of hospitalization. Additionally, the timing of drug consumption and the treatment process in elderly women with abnormal laboratory parameters should be evaluated more carefully.

Keywords: Actemra, COVID-19, Outcome, Tocilizumab, Treatment

Full-Text [PDF 357 kb] (154 Downloads)

Type of Study: orginal article | Subject: Other

References

1. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 2020; 395(10229):1054-62. http://dx.doi.org/10.1016/S0140-6736(20)30566-3 [DOI:10.1016/S0140-6736(20)30566-3] [PMID]

2. Hafez W, Ziade MA, Arya A, Saleh H, Abdelshakor M, Fadl Alla O, et al. Treatment outcomes of Tocilizumab in critically-ill COVID-19 patients, single-centre retrospective study. Antibiotics (Basel) 2022; 11(2):241. http://dx.doi.org/10.3390/antibiotics11020241 [DOI:10.3390/antibiotics11020241] [PMID] [PMCID]

3. Moreno-García E, Rico V, Albiach L, Agüero D, Ambrosioni J, Bodro M , et al. Tocilizumab is associated with reduction of the risk of ICU admission and mortality in patients with SARS-CoV-2 infection. medRxiv 2020. [DOI:10.1101/2020.06.05.20113738]

4. Jin Y, Yang H, Ji W, Wu W, Chen S, Zhang W, et al. Virology, epidemiology, pathogenesis, and control of COVID-19. Viruses 2020; 12(4):372. http://dx.doi.org/10.3390/v12040372 [DOI:10.3390/v12040372] [PMID] [PMCID]

5. Pasrija R, Naime M. The deregulated immune reaction and cytokines release storm (CRS) in COVID-19 disease. Int. Immunopharmaco 2021; 90(107225):107225. http://dx.doi.org/10.1016/j.intimp.2020.107225 [DOI:10.1016/j.intimp.2020.107225] [PMID] [PMCID]

6. Mangalmurti N, Hunter CA. Cytokine storms: Understanding COVID-19. Immunity 2020; 53(1):19-25. http://dx.doi.org/10.1016/j.immuni.2020.06.017 [DOI:10.1016/j.immuni.2020.06.017] [PMID] [PMCID]

7. Que Y, Hu C, Wan K, Hu P, Wang R, Luo J, et al. Cytokine release syndrome in COVID-19: a major mechanism of morbidity and mortality. Int. Rev. Immunol 2022; 41(2):217-30. http://dx.doi.org/10.1080/08830185.2021.1884248 [DOI:10.1080/08830185.2021.1884248] [PMID] [PMCID]

8. Kobayashi T, Tanaka K, Fujita T, Umezawa H, Amano H, Yoshioka K, et al. Bidirectional role of IL-6 signal in pathogenesis of lung fibrosis. Respir. Res 2015; 16(1):99. http://dx.doi.org/10.1186/s12931-015-0261-z [DOI:10.1186/s12931-015-0261-z] [PMID] [PMCID]

9. Tanaka T, Narazaki M, Kishimoto T. Immunotherapeutic implications of IL-6 blockade for cytokine storm. Immunotherapy 2016;8(8):959-70. http://dx.doi.org/10.2217/imt-2016-0020 [DOI:10.2217/imt-2016-0020] [PMID]

10. Kow CS, Hasan SS. Interleukin-6 blockade with tocilizumab in COVID-19: Does it live up to its hype? Pulmonology 2021; 27(1):86-7. http://dx.doi.org/10.1016/j.pulmoe.2020.10.004 [DOI:10.1016/j.pulmoe.2020.10.004] [PMID] [PMCID]

11. Ogata A, Kato Y, Higa S, Yoshizaki K. IL-6 inhibitor for the treatment of rheumatoid arthritis: A comprehensive review. Mod. Rheumatol 2019; 29(2):258-67. http://dx.doi.org/10.1080/14397595.2018.1546357 [DOI:10.1080/14397595.2018.1546357] [PMID]

12. Song S-NJ, Yoshizaki K. Tocilizumab for treating rheumatoid arthritis: an evaluation of pharmacokinetics/pharmacodynamics and clinical efficacy. Expert Opin. Drug Metab. Toxicol 2015; 11(2):307-16. http://dx.doi.org/10.1517/17425255.2015.992779 [DOI:10.1517/17425255.2015.992779] [PMID]

13. Maude SL, Barrett D, Teachey DT, Grupp SA. Managing cytokine release syndrome associated with novel T cell-engaging therapies. Cancer J 2014; 20(2):119-22. http://dx.doi.org/10.1097/PPO.0000000000000035 [DOI:10.1097/PPO.0000000000000035] [PMID] [PMCID]

14. Fernández-Ruiz M, López-Medrano F, Pérez-Jacoiste Asín MA, Maestro de la Calle G, Bueno H, Caro-Teller JM, et al. Tocilizumab for the treatment of adult patients with severe COVID-19 pneumonia: A single-center cohort study. J. Med. Virol 2021; 93(2):831-42. http://dx.doi.org/10.1002/jmv.26308 [DOI:10.1002/jmv.26308] [PMID] [PMCID]

15. Winthrop KL, Mariette X. To immunosuppress: whom, when and how? That is the question with COVID-19. ARD 2020; 1; 79(9):1129-31. [DOI:10.1136/annrheumdis-2020-218694] [PMID] [PMCID]

16. Diaz RM, García MA, Muñoz FJ, Perez LE, Gonzalez MM, Bermejo JA, et al. Does timing matter on tocilizumab administration? Clinical, analytical and radiological outcomes in COVID-19.Eur J Hosp Pharm 2022 1; 29(6):340-5. http://doi.org/10.1136/ejhpharm-2020-002669 [DOI:10.1136/ejhpharm-2020-002669] [PMID] [PMCID]

17. Dhasmana DJ. Dexamethasone in hospitalized patients with Covid-19. N Engl J Med 2021 25. [URL]

18. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 2020; 395(10229):1054-62. http://dx.doi.org/10.1016/S0140-6736(20)30566-3 [DOI:10.1016/S0140-6736(20)30566-3] [PMID]

19. Casas-Rojo JM, Antón-Santos JM, Millán-Núñez-Cortés J, Lumbreras-Bermejo C, Ramos-Rincón JM, Roy-Vallejo E, et al. Clinical characteristics of patients hospitalized with COVID-19 in Spain: results from the SEMI-COVID-19 Registry. Rev. Clin. Esp 2020; 220(8):480-94. http://dx.doi.org/10.1016/j.rceng.2020.07.003 [DOI:10.1016/j.rceng.2020.07.003] [PMCID]

20. Wu C, Chen X, Cai Y, Xia J, Zhou X, Xu S, et al. Risk factors associated with acute respiratory distress syndrome and death in patients with Coronavirus disease 2019 pneumonia in Wuhan, China. JAMA Intern. Med 2020; 180(7):934-43. http://dx.doi.org/10.1001/jamainternmed.2020.0994. [DOI:10.1001/jamainternmed.2020.0994] [PMID] [PMCID]

21. Wiersinga WJ, Rhodes A, Cheng AC, Peacock SJ, Prescott HC. Pathophysiology, transmission, diagnosis, and treatment of Coronavirus disease 2019 (COVID-19): A review. JAMA 2020; 324(8):782-93. http://dx.doi.org/10.1001/jama.2020.12839. [DOI:10.1001/jama.2020.12839] [PMID]

22. Guaraldi G, Meschiari M, Cozzi-Lepri A, Milic J, Tonelli R, Menozzi M, et al. Tocilizumab in patients with severe COVID-19: a retrospective cohort study. Lancet Rheumatol 2020 1; 2(8):e474-84. http://dx.doi.org/10.1016/S2665-9913(20)30173-9 [DOI:10.1016/S2665-9913(20)30173-9] [PMID]

23. Ltd FHLR. GlobeNewswire News Room. 2020 [cited 2024 Oct 20]. Roche's phase III EMPACTA study showed Actemra/RoActemra reduced the likelihood of needing mechanical ventilation in hospitalised patients with COVID-19 associated pneumonia. Available from: https://www.globenewswire.com/news-release/2020/09/18/2095621/0/en/Roche-s-phase-III-EMPACTA-study-showed-Actemra-RoActemra-reduced-the-likelihood-of-needing-mechanical-ventilation-in-hospitalised-patients-with-COVID-19-associated-pneumonia.html [URL]

24. Roche provides an update on the phase III COVACTA trial of Actemra/RoActemra in hospitalised patients with severe COVID-19 associated pneumonia. https://www.roche.com/media/releases/med-cor-2020-07-29.htm. [URL]

25. De Rossi N, Scarpazza C, Filippini C, Cordioli C, Rasia S, Mancinelli CR, et al. Early use of low dose tocilizumab in patients with COVID-19: A retrospective cohort study with a complete follow-up. EClinicalMedicine 2020; 25(100459):100459. http://dx.doi.org/10.1016/j.eclinm.2020.100459 [DOI:10.1016/j.eclinm.2020.100459] [PMID] [PMCID]

26. Liu B, Li M, Zhou Z, Guan X, Xiang Y. Can we use interleukin-6 (IL-6) blockade for coronavirus disease 2019 (COVID-19)-induced cytokine release syndrome (CRS)? J.Autoimmunity 2020; 111(102452):102452. http://dx.doi.org/10.1016/j.jaut.2020.102452 [DOI:10.1016/j.jaut.2020.102452] [PMID] []

27. Gupta S, Wang W, Hayek SS, Chan L, Mathews KS, Melamed ML, et al. Association between early treatment with tocilizumab and mortality among critically ill patients with COVID-19. JAMA Intern. Med 2021; 181(1):41-51. http://dx.doi.org/10.1001/jamainternmed.2020.6252 [DOI:10.1001/jamainternmed.2020.6252] [PMID] [PMCID]

28. Salvarani C, Dolci G, Massari M, Merlo DF, Cavuto S, Savoldi L, et al. Effect of tocilizumab vs standard care on clinical worsening in patients hospitalized with COVID-19 pneumonia: A randomized clinical trial: A randomized clinical trial. JAMA Intern. Med 2021; 181(1):24-31. http://dx.doi.org/10.1001/jamainternmed.2020.6615 [DOI:10.1001/jamainternmed.2020.6615] [PMID] [PMCID]

29. Kaye AG, Siegel R. The efficacy of IL-6 inhibitor Tocilizumab in reducing severe COVID-19 mortality: a systematic review. PeerJ 2020; 8(e10322):e10322. http://dx.doi.org/10.7717/peerj.10322 [DOI:10.7717/peerj.10322] [PMID] [PMCID]

30. Moreno-García E, Rico V, Albiach L, Agüero D, Ambrosioni J, Bodro M, et al. Tocilizumab is associated with reduced risk of ICU admission and mortality in patients with SARS-CoV-2 infection 2020. http://dx.doi.org/10.1101/2020.06.05.20113738 [DOI:10.1101/2020.06.05.20113738]

31. Malgie J, Schoones JW, Pijls BG. Decreased mortality in Coronavirus disease 2019 patients treated with tocilizumab: A rapid systematic review and meta-analysis of observational studies. Clin. Infect. Dis 2021; 72(11):e742-9. http://dx.doi.org/10.1093/cid/ciaa1445 [DOI:10.1093/cid/ciaa1445] [PMID] [PMCID]

32. Sciascia S, Aprà F, Baffa A, Baldovino S, Boaro D, Boero R, et al. Pilot prospective open, single-arm multicentre study on off-label use of tocilizumab in patients with severe COVID-19. Clin. Exp. Rheumatol 2020;38(3):529-32. [Google Scholar]

33. Toniati P, Piva S, Cattalini M, Garrafa E, Regola F, Castelli F, et al. Tocilizumab for the treatment of severe COVID-19 pneumonia with hyperinflammatory syndrome and acute respiratory failure: A single center study of 100 patients in Brescia, Italy. Autoimmun. Rev 2020; 19(7):102568. http://dx.doi.org/10.1016/j.autrev.2020.102568 [DOI:10.1016/j.autrev.2020.102568] [PMID] [PMCID]

34. Furlow B. COVACTA trial raises questions about tocilizumab's benefit in COVID-19. Lancet Rheumatol 2020; 2(10):e592. http://dx.doi.org/10.1016/s2665-9913(20)30313-1 [DOI:10.1016/S2665-9913(20)30313-1] [PMID]

35. Albertini L, Soletchnik M, Razurel A, Cohen J, Bidegain F, Fauvelle F, et al. Observational study on off-label use of tocilizumab in patients with severe COVID-19. Eur. J. Hosp. Pharm. Sci. Pract 2021; 28(1):22-7. http://dx.doi.org/10.1136/ejhpharm-2020-002414 [DOI:10.1136/ejhpharm-2020-002414] [PMID] [PMCID]

36. Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, et al. Current concepts in the diagnosis and management of cytokine release syndrome. Blood 2014; 124(2):188-95. http://dx.doi.org/10.1182/blood-2014-05-552729 [DOI:10.1182/blood-2014-05-552729] [PMID] [PMCID]

37. Luo P, Liu Y, Qiu L, Liu X, Liu D, Li J. Tocilizumab treatment in COVID-19: A single center experience. J. Med. Virol 2020; 92(7):814-8. http://dx.doi.org/10.1002/jmv.25801 [DOI:10.1002/jmv.25801] [PMID] [PMCID]

38. Biran N, Ip A, Ahn J, Go RC, Wang S, Mathura S, et al. Tocilizumab among patients with COVID-19 in the intensive care unit: a multicentre observational study. Lancet Rheumatol 2020; 2(10):e603-12. http://dx.doi.org/10.1016/S2665-9913(20)30277-0 [DOI:10.1016/S2665-9913(20)30277-0] [PMID]

39. Keshtkar Rajabi S, Divsalar F, Arabi M, Abbasi MA. Prevalence and risk factors of cardiac arrhythmia in COVID-19 patients. Int. J. Cardiovasc. Pract 2024; 9(1). http://dx.doi.org/10.5812/intjcardiovascpract-143916 [DOI:10.5812/intjcardiovascpract-143916]